June 29, 2022
The fight against fat
Back when Novo Nordisk decided to enter the obesity arena, we thought this was a brilliant move. Victoza their lead diabetes GLP-1 like most GLP-1’s has proven weight loss benefits, was easy to administer and few adverse events. Heck they really didn’t have to do much other than get Victoza approved for weight loss and rename it. There was the additional benefit that their rival Lilly was not yet in the weight loss arena which gave them basically open field running. Lastly, we reasoned patients would fall in love with any therapy that required just one . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
